Aktis Oncology, Inc. (AKTS)
18.15
+0.41
(+2.31%)
USD |
NASDAQ |
Oct 09, 16:00
18.14
-0.02
(-0.08%)
After-Hours: 20:00
Aktis Oncology EPS Diluted (Quarterly) : -0.4364 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.4364 |
| March 31, 2026 | -0.3315 |
| December 31, 2025 | -0.2835 |
| Date | Value |
|---|---|
| June 30, 2025 | -0.3267 |
| March 31, 2025 | -0.2806 |
| December 31, 2024 | -0.2295 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -24.14M |
| Revenue (Quarterly) | 3.384M |
| Total Expenses (Quarterly) | 27.53M |
| Enterprise Value | 497.96M |
| Gross Profit Margin (Quarterly) | 74.02% |
| Profit Margin (Quarterly) | -713.5% |
| Earnings Yield | -7.59% |
| Normalized Earnings Yield | -7.593 |